DE3778122D1 - Pharmazeutische zusammensetzungen von rekombinanten interleukin-2 und herstellungsverfahren. - Google Patents

Pharmazeutische zusammensetzungen von rekombinanten interleukin-2 und herstellungsverfahren.

Info

Publication number
DE3778122D1
DE3778122D1 DE8787115694T DE3778122T DE3778122D1 DE 3778122 D1 DE3778122 D1 DE 3778122D1 DE 8787115694 T DE8787115694 T DE 8787115694T DE 3778122 T DE3778122 T DE 3778122T DE 3778122 D1 DE3778122 D1 DE 3778122D1
Authority
DE
Germany
Prior art keywords
pharmaceutical compositions
recombinant interleukin
production method
solubilizer
stabilizers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE8787115694T
Other languages
English (en)
Inventor
Ze Ev Shaked
Tracy Stewart
James William Thomson
Pamela Hirtzer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Cetus Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cetus Corp filed Critical Cetus Corp
Application granted granted Critical
Publication of DE3778122D1 publication Critical patent/DE3778122D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE8787115694T 1986-10-27 1987-10-26 Pharmazeutische zusammensetzungen von rekombinanten interleukin-2 und herstellungsverfahren. Expired - Lifetime DE3778122D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US92338386A 1986-10-27 1986-10-27

Publications (1)

Publication Number Publication Date
DE3778122D1 true DE3778122D1 (de) 1992-05-14

Family

ID=25448603

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8787115694T Expired - Lifetime DE3778122D1 (de) 1986-10-27 1987-10-26 Pharmazeutische zusammensetzungen von rekombinanten interleukin-2 und herstellungsverfahren.

Country Status (9)

Country Link
EP (1) EP0268110B1 (de)
JP (1) JPS63122628A (de)
AT (1) ATE74512T1 (de)
AU (1) AU614066B2 (de)
CA (1) CA1292686C (de)
DE (1) DE3778122D1 (de)
ES (1) ES2036558T3 (de)
GR (1) GR3004479T3 (de)
IE (1) IE60890B1 (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5037644A (en) * 1986-10-27 1991-08-06 Cetus Corporation Pharmaceutical compositions of recombinant interleukin-2 and formulation processes
US4931543A (en) * 1987-05-11 1990-06-05 Cetus Corporation Process for recovering microbially produced interleukin-2
US6054441A (en) * 1987-10-28 2000-04-25 Pro-Neuron, Inc. Oxypurine nucleosides and their congeners, and acyl derivatives thereof, for improvement of hematopoiesis
KR910700061A (ko) * 1988-12-06 1991-03-13 오스카 아끼히꼬 인터로이킨-1β의 안정화 조성물
US6586222B1 (en) 1989-08-16 2003-07-01 Chiron Corporation Recombinant PR-3 and compositions thereof
US5843693A (en) * 1989-08-16 1998-12-01 Chiron Corporation Assay method for screening for inhibitors of proTNF conversion
US5998378A (en) * 1989-08-16 1999-12-07 Chiron Corporation Compositions for the inhibition of TNF hormone formation and uses thereof
JPH0791318B2 (ja) * 1989-09-21 1995-10-04 三井東圧化学株式会社 蛋白質水溶液、蛋白質水溶液の濃度増大方法および蛋白質製剤
US5830452A (en) * 1990-11-20 1998-11-03 Chiron Corporation Method for enhancing the anti-tumor therapeutic index of interleukin-2
US6063764A (en) * 1992-06-01 2000-05-16 Washington University & Chiron Corp. Method for using lipoprotein associated coagulation inhibitor to treat sepsis
US20030171292A1 (en) 1992-06-01 2003-09-11 Creasey Abla A. Method for using lipoprotein associated coagulation inhibitor to treat sepsis
KR100303872B1 (ko) * 1992-10-02 2001-11-22 크리스터 발스트룀, 프레드릭 베르그, 하랄트 알름 응고인자ⅷ제형을포함하는조성물,이것의제조방법및안정화제로서의계면활성제의사용방법
WO1994009138A1 (en) * 1992-10-20 1994-04-28 Cetus Oncology Corporation Interleukin-6 receptor antagonists
SE9301581D0 (sv) * 1993-05-07 1993-05-07 Kabi Pharmacia Ab Protein formulation
US6288030B1 (en) 1993-12-22 2001-09-11 Amgen Inc. Stem cell factor formulations and methods
WO2003055442A2 (en) 2001-10-15 2003-07-10 Chiron Corporation Treatment of sepsis by low dose administration of tissue factor pathway inhibitor (tfpi)
DK1682178T3 (da) 2003-11-04 2010-10-04 Novartis Vaccines & Diagnostic Fremgangsmåder til terapi af cancere der udtrykker CD-40-antigenet
DE602004028272D1 (de) 2003-11-04 2010-09-02 Novartis Vaccines & Diagnostic Verwendung von antagonisten-anti-cd40-monoklonalen antikörpern zur behandlung von multiplem myelom
CA2544852A1 (en) 2003-11-04 2005-05-19 Chiron Corporation Methods of therapy for solid tumors expressing the cd40 cell-surface antigen
DE602004028270D1 (de) 2003-11-04 2010-09-02 Novartis Vaccines & Diagnostic Verwendung von antagonisten-anti-cd40-antikörpern zur behandlung von chronisch lymphozytischer leukämie
JP4810431B2 (ja) 2003-11-04 2011-11-09 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド Ｂ細胞に関連する癌に対する治療方法
GB0404586D0 (en) * 2004-03-01 2004-04-07 Britannia Pharmaceuticals Ltd Improvements in or relating to organic materials
KR100624013B1 (ko) 2004-06-25 2006-09-19 주식회사 녹십자홀딩스 동결건조된 알부민 비함유 재조합 사람 혈액응고 제 8인자 제제
JP5518608B2 (ja) * 2010-07-09 2014-06-11 ロート製薬株式会社 粘膜適用液状組成物
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
WO2012075111A1 (en) 2010-11-30 2012-06-07 Novartis Ag Uses of anti-cd40 antibodies in combination therapy for b cell-related cancers
EP2646459B1 (de) 2010-12-02 2020-01-08 Bionor Immuno AS Peptidgerüstentwurf
CN103347892B (zh) 2011-01-06 2016-11-02 比奥诺尔免疫有限公司 单体和多聚体免疫原性肽
DE102012101864A1 (de) * 2012-03-06 2013-09-12 Gramme-Revit Gmbh Mittel zur Behandlung von Allergien und anderen Erkrankungen
EP2859011B1 (de) 2012-06-06 2019-12-11 Bionor Immuno AS Peptide aus viralen proteinen zur verwendung als immunogene oder nachweisreagenzien
UA105278C2 (ru) 2012-09-06 2014-04-25 Інститут Біології Клітини Нан України Способ получения каталитически активных антител (абзимов) с сиалидазной активностью
AU2014257125B2 (en) 2013-04-23 2019-04-18 Cedars-Sinai Medical Center Systems and methods for recording simultaneously visible light image and infrared light image from fluorophores
MX2016009284A (es) 2014-01-17 2016-10-07 Cedars Sinai Medical Center Construcciones dirigidas a receptor y sus usos.
MX2016016507A (es) 2014-06-12 2017-04-27 Cedars Sinai Medical Center Composiciones y metodos para tratar canceres.
KR101799557B1 (ko) 2014-07-22 2017-11-20 주식회사 레모넥스 생리활성 물질 또는 단백질 전달용 조성물 및 이의 용도
EP3215186A4 (de) 2014-11-04 2018-10-24 University of Southern California Zusammensetzungen und verfahren zur behandlung von hif-1 alpha-überexprimierenden karzinomen
ES2842849T3 (es) 2015-05-05 2021-07-15 Univ California Péptidos CTL H3.3 y usos de los mismos
US10441644B2 (en) 2015-05-05 2019-10-15 The Regents Of The University Of California H3.3 CTL peptides and uses thereof
US11567078B2 (en) 2015-08-31 2023-01-31 Cedars-Sinai Medical Center Blood cell biomarker for late onset Alzheimer's disease
WO2017138924A1 (en) 2016-02-09 2017-08-17 Autotelic Llc Compositions and methods for treating pancreatic cancer
KR20180103817A (ko) 2016-02-09 2018-09-19 오토텔릭 엘엘씨 암을 치료하기 위한 조성물과 방법
WO2018143787A1 (ko) 2017-02-06 2018-08-09 주식회사 레모넥스 생리활성물질 전달체
CN110475546A (zh) 2017-02-06 2019-11-19 雷莫内克斯生物制药有限公司 生理活性物质载体
WO2019023245A1 (en) 2017-07-25 2019-01-31 Cedars-Sinai Medical Center METHODS OF TREATING HEPATIC DISEASES
KR102152348B1 (ko) 2017-09-05 2020-09-08 주식회사 레모넥스 세포 운명 조절용 조성물
KR20210089719A (ko) 2018-11-08 2021-07-16 세다르스-신나이 메디칼 센터 Hla-감작된 환자에서 탈감작화 및 신장 이식의 개선을 위한 클라자키주맙의 용도
BR112021010615A2 (pt) 2018-12-20 2021-11-03 Cedars Sinai Medical Center Clazakizumab no tratamento de rejeição crônica de transplante de órgãos mediada por anticorpos
US20230109142A1 (en) 2020-02-14 2023-04-06 Immunor As Corona virus vaccine
JP2023549191A (ja) * 2020-11-13 2023-11-22 江蘇恒瑞医薬股▲ふん▼有限公司 ヒトインターロイキン２の変異体又はその誘導体を含む医薬組成物及びその用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2652636A1 (de) * 1976-11-19 1978-05-24 Hans Uwe Dr Rer Nat Wolf Verfahren zur stabilisierung von proteinen und verwandten verbindungen waehrend ihrer reinigung, isolierung und lagerung
US4457916A (en) * 1982-08-31 1984-07-03 Asahi Kasei Kogyo Kabushiki Kaisha Method for stabilizing Tumor Necrosis Factor and a stable aqueous solution or powder containing the same
EP0211835B1 (de) * 1984-03-28 1990-01-03 Cetus Corporation Pharmazeutische zusammensetzungen von mikrobenerzeugtem interleukin-2
DE3583880D1 (de) * 1984-04-09 1991-10-02 Takeda Chemical Industries Ltd Stabile interleukin-2-zusammensetzung.
CA1297003C (en) * 1985-09-20 1992-03-10 Jack H. Nunberg Composition and method for treating animals
US4822605A (en) * 1986-02-18 1989-04-18 Exovir, Inc. Compositions and methods employing the same for the treatment of viral and cancerous skin lesions and the like

Also Published As

Publication number Publication date
JPS63122628A (ja) 1988-05-26
IE60890B1 (en) 1994-08-24
CA1292686C (en) 1991-12-03
ATE74512T1 (de) 1992-04-15
AU614066B2 (en) 1991-08-22
IE872844L (en) 1988-04-27
GR3004479T3 (de) 1993-03-31
EP0268110A1 (de) 1988-05-25
EP0268110B1 (de) 1992-04-08
ES2036558T3 (es) 1993-06-01
AU8018187A (en) 1988-04-28

Similar Documents

Publication Publication Date Title
DE3778122D1 (de) Pharmazeutische zusammensetzungen von rekombinanten interleukin-2 und herstellungsverfahren.
ATE111744T1 (de) Pharmazeutische zusammensetzungen von rekombinantem beta-interferon und herstellungsverfahren.
ES2132066T3 (es) Procedimiento para la produccion de proteina biologicamente activa (v.g. tfg).
DK0388220T3 (da) Præparater til vedvarende frigivelse af klorhexidin
ATE72988T1 (de) Fettsaeure-zusammensetzungen.
NL930119I2 (nl) Farmaceutische en veterinaire preparaten van cysteine-125-verminderde muteïnen van interleukine-2 ende produktie daarvan.
DK16890A (da) Antiviral eller antibakteriel forbindelse og frem gangsmaade til anvendelse heraf
ATE66817T1 (de) Stabile formulierung biologisch aktiver proteine zur parenteralen injektion.
IT1232827B (it) Proteine biologicamente attive, formulazioni che le contengono e metodo per prepararle ed applicarle
FR2680507B1 (fr) Nouvelles naphtylethylurees et naphtylethylthiourees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2707638B1 (fr) Nouveaux dérivés d'amino-acides, leurs procédés de préparation et leur application thérapeutique.
ATE175213T1 (de) Ch0ndromodulin-ii protein
PT84130A (fr) Procede de preparation de nouveaux derives de 3-alkoxyflavones et de leurs compositions therapeutiques
FR2605223B1 (fr) Compositions therapeutiques stables a base d' huile vegetale hydrophobe et son procede de preparation
IT1197892B (it) Composizioni farmaceutiche ad attivita' cicatrizzante
BG60657B2 (en) Human recombinant interleukin-2 muteins

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: CHIRON CORP. (N.D.GES.D. STAATES DELAWARE), EMERYV

8327 Change in the person/name/address of the patent owner

Owner name: NOVARTIS VACCINES AND DIAGNOSTICS,INC.(N.D.GES, US